In a comparison study, subcutaneous mirikizumab proved superior to subcutaneous in achieving skin clearance in patients with plaque psoriasis…... [Read More]
Study Finds Mirikizumab Superior to Secukinumab for Plaque Psoriasis
Search results for: plaque psoriasis
Apremilast Promising for Plaque Psoriasis
Apremilast has been shown to improve the signs and symptoms of mild to moderate plaque psoriasis in adults, according to new research…... [Read More]
Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis
In a phase 3, comparator study in adults with plaque psoriasis, patients taking
risankizumab achieved greater skin clearance than those taking secukinumab…... [Read More]
IV Meloxicam Stalls at FDA; Plus Health Canada Approves Risankizumab for Plaque Psoriasis
In a second response letter, the FDA has cited the onset and duration of intravenous meloxicam, a non-opioid pain treatment, as concerns that it fails to meet prescriber expectations…... [Read More]
Mirikizumab Promising for Plaque Psoriasis
During a 16-week study, patients with plaque psoriasis taking mirikizumab experienced higher response rates and skin clearance compared with placebo…... [Read More]
FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Receive FDA Priority Review
The FDA has approved halobetasol propionate lotion as a topical treatment for plaque psoriasis…... [Read More]
Plaque Psoriasis Treatments: BMS-986165 Promising & Adalimumab Biosimilar Demonstrates Equivalence
According to new data, BMS-986165, an oral, selective tyrosine kinase 2 inhibitor, may be safe and effective for treating plaque psoriasis…... [Read More]
FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis
The FDA has approved a combination of amlodipine and celecoxib, which may lower serum creatinine, for treating osteoarthritis pain and hypertension…... [Read More]
Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis
On the basis of data from multiple clinical trials, the FDA has approved certolizumab pegol for treating moderate to severe plaque psoriasis…... [Read More]
Ustekinumab Approved for Use in Adolescents with Plaque Psoriasis
In October, the FDA approved ustekinumab to treat patients 12 years or older who have moderate to severe plaque psoriasis…... [Read More]
- 1
- 2
- 3
- …
- 17
- Next Page »